EP0585399A1 - Traitement de carcinome colo-rectal a l'aide d'oligonucleotides non codants par rapport au proto-oncogene c-myb - Google Patents

Traitement de carcinome colo-rectal a l'aide d'oligonucleotides non codants par rapport au proto-oncogene c-myb

Info

Publication number
EP0585399A1
EP0585399A1 EP92913962A EP92913962A EP0585399A1 EP 0585399 A1 EP0585399 A1 EP 0585399A1 EP 92913962 A EP92913962 A EP 92913962A EP 92913962 A EP92913962 A EP 92913962A EP 0585399 A1 EP0585399 A1 EP 0585399A1
Authority
EP
European Patent Office
Prior art keywords
seq
oligonucleotide
myb
mer
oligodeoxynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92913962A
Other languages
German (de)
English (en)
Other versions
EP0585399A4 (en
Inventor
Bruno Calabretta
Alan M. Gewirtz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University of Commonwealth System of Higher Education
Original Assignee
Temple University of Commonwealth System of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple University of Commonwealth System of Higher Education filed Critical Temple University of Commonwealth System of Higher Education
Publication of EP0585399A1 publication Critical patent/EP0585399A1/fr
Publication of EP0585399A4 publication Critical patent/EP0585399A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Definitions

  • the invention relates to antisense oligonucleotides to proto-oncogenes, in particular antisense oligonucleotides to the c-myb gene, and the use of such oligonucleotides as antineoplastic agents.
  • the proto-oncogene c-myb is the normal cellular homologue of the avian myeloblastosis virus-transforming gene v-myb.
  • the c-myjo gene codes for a nuclear protein expressed primarily in hematopoietic cells. It is a proto-oncogene, that is, it codes for a protein which is required for the survival of normal, non-tumor cells.
  • Oncogenes are genes whose expression within a cell provides some function in the transformation from normal to tumor cell.
  • the human c-myb gene has been isolated, cloned, and seguenced. Maj llo et al. , Proc. Natl. Acad. Sci.
  • Antisense oligonucleotides to human c-myb mRNA that is, oligonucleotides having a nucleotide sequence complementary to the mRNA transcript of the c-myb gene, are disclosed in our commonly assigned, U.S. Patent No. 5,098,890, the entire disclosure of which is incorporated herein by reference.
  • C-myb antisense oligonucleotides are disclosed therein as being useful for the treatment of hematologic neoplasms, and for immunosuppression.
  • C-myb antisense oligonucleotides have not heretofore been known to have antiproliferative activity against neoplastic diseases other than those of a hematologic nature.
  • Colorectal cancer is the second most common malignancy of the adult population in the United States (excluding skin cancer) . Its occurrence is exceeded only by lung cancer in males and breast cancer among females. A similar incidence has been reported in many other countries.
  • a large majority of rectal and colonic malignancies are adenocarcinomas, i.e., they originate in glandular epithelium. Colorectal carcinoma generally progresses from adenoma, to in situ adenocarcinoma , and then to invasive adenocarcinoma.
  • Colorectal cancers are classified based on the "Duke's classification" into four different stages: A, B, C and D.
  • stage A the cancer is limited to the mucosa and submucosa, with a 90% five- year survival.
  • stage B the cancer extends into muscularis or serosa, with a 60-75% five-year survival.
  • Stage C cancer involves regional lymph nodes, with a 30- 40% five-year survival.
  • stage D metastases in the liver, bone and lungs are commonly found.
  • Stage D patients typically have only a 5% five-year survival rate.
  • the current approach to colorectal cancer treatment is primarily surgical. The overall five-year survival rate for all patients undergoing resection for colonic malignancy is approximately 50%.
  • 5-fluorouracil 5-fluorouracil
  • 5-FU 5-fluorouracil
  • 5-FU 5-fluorouracil
  • 5-FU is administered to patients with metastases to the liver, but temporary improvement is obtained only in 25% or less of cases, and overall survival is not significantly affected.
  • 5-FU treatment does not spare normal dividing cells, and is associated with the usual toxicity of chemotherapy, i.e.
  • Elevated c-myb expression has been associated with colon carcinoma (Trainer et a_L. , Int. J. Cancer. 41,
  • the invention provides a method for treating human colorectal carcinomas characterized by c-myb gene expression. An effective amount of one or more c-myb antisense oligonucleotides is administered to an individual in need of such treatment.
  • Each oligonucleotide has a nucleotide sequence complementary to at least a portion of the mRNA trans ⁇ cript of the human c-myb gene.
  • the oligonucleotide is hybridizable to the mRNA transcript.
  • the oligonucleotide is at least a 12-mer oligonucleotide, that is, an oligomer containing at least 12 nucleotide residues.
  • the oligomer is advantageously a 12-mer to a 40-mer, preferably an oligodeoxynucleotide.
  • oligonucleotides smaller than 12-mers are statistically more likely to hybridize with non-targeted sequences, and for this reason may be less specific. In addition, a single mismatch may destabilize the hybrid. While oligonucleotides larger than 40-mers may be utilized, uptake may be more difficult. Moreover, partial matching of long sequences may lead to non-specific hybridization, and non-specific effects.
  • the oligonucleotide is a 15- to 30-mer oligodeoxynucleotide, more advantageously an 18- to 26-mer.
  • the oligonucleotide is a 15- to 21-mer oligodeoxynucleotide.
  • oligonucleotides having a sequence complementary to any region of the c-myb gene find utility in the present invention
  • oligodeoxynucleotides complementary to a portion of the c-myb mRNA transcript including the translation initiation codon are particularly preferred.
  • oligonucleotide includes both oligomers of ribonucleotide, i.e., oligoribonucleotides, and oligomers of deoxyribonucleotide, i.e., oligo- deoxyribonucleotides (also referred to herein as "oligodeoxynucleotides”) . Oligodeoxynucleotides are preferred.
  • oligonucleotide also includes oligomers which may be large enough to be termed “polynucleo- tides”.
  • oligonucleotide and “oligodeoxynucleotide” include not only oligomers and polymers of the common biologically significant nucleotides, i.e., the nucleotides adenine ("A"), deoxyadenine ("dA”) , guanine (“G”) , deoxyguanine (“dG”) , cytosine (“C”) , deoxycytosine (“dC”) , thymine (“T”) and uracil (“U”) , but also include oligomers and polymers hybridizable to the c-myb mRNA transcript which may contain other nucleotides.
  • A adenine
  • dA deoxyadenine
  • G guanine
  • dG deoxyguanine
  • C cytosine
  • dC deoxycytosine
  • T thymine
  • U uracil
  • oligonucleotide and “oligodeoxynucleotide” may include oligomers and polymers wherein one or more purine or pyrimidine moieties, sugar moieties or internucleotide linkages is chemically modified.
  • oligonucleotide is thus understood to also include oligomers which may properly be designated as “oligonucleosides" because of modification of the internucleotide phosphodiester bond.
  • modified oligonucleotides include, for example, the alkylphosphonate oligonucleosides, discussed below.
  • phosphorothioate oligonucleotide means an oligonucleotide wherein one or more of the internucleotide linkages is a phosphorothioate group,
  • alkylphosphonate oligonucleoside is meant an oligonucleotide wherein one or more of the internucleotide linkages is an alkylphosphonate group
  • R is an alkyl group preferably methyl or ethyl.
  • downstream when used in reference to a direction along a nucleotide sequence means the 5' ⁇ 3' direction.
  • upstream means the 3' ⁇ 5' direction.
  • c-myb mRNA transcript means the presently known MRNA transcript of the human c-myb gene, or any further transcripts which may be elucidated. Brief Description of the Figures
  • Figures 1A and IB comprise graphs recording the (A) proliferation and (B) 3 H-thymidine incorporation, of colon carcinoma cell lines LoVo/Dx, LoVo, Colo 205 and HT 29, cultured in the presence of culture medium alone (“MEDIUM”) , or medium to which has been added c-myb sense (“SENSE”) or antisense (“ANTISENSE”) oligodeoxynucleotide.
  • MEDIUM culture medium alone
  • SENSE c-myb sense
  • ANTISENSE antisense
  • Figures 2A and 2B record the dose-depeident inhibition of (A) 3 H-thymidine uptake and (B) ' cell proliferation, of carcinoma cell lines Colo 205, LoVo/Dx and LoVo treated with c-myb sense (“SENSE”) or varying amounts of antisense ("AS”) oligodeoxynucleotide.
  • SENSE c-myb sense
  • AS antisense
  • c-myb expression is not an absolute requirement for the proliferation of neoplastic epithelial cells as shown by the complete independence of proliferation of some colorectal car ⁇ cinoma cell lines from the synthesis of c-myb protein.
  • a particular patient's carcinoma expresses c- myb. and is therefore potentially treatable with antisense oligonucleotides, can be readily determined by hybridization studies utilizing appropriate oligonucleotide probes for detecting c-myb mRNA.
  • a representative screening technique is described hereinafter in Example 2, it being understood that other methods for determining the level of a gene's expression are well-known to those skilled in the art. Such other methods include, for example, reverse transcriptase polymerase chain reaction (RT-PCR) analysis.
  • RT-PCR reverse transcriptase polymerase chain reaction
  • the putative DNA sequence complementary to the mRNA transcript of the human c-myb gene has been reported in Majello et a_L. , Proc. Natl. Acad. Sci. U.S.A. 83, 9636-9640 (1986) and in U.S. Patent No. 5,098,890.
  • Majello et al. further disclose the predicted 640 amino acid sequence of the putative c- mvb protein.
  • the initiation codon ATG appears at position 114, preceded by a 5'-untranslated region.
  • the termination codon TGA at position 2034 is followed by a 3'-untranslated region spanning about 1200 nucleotides, which is followed by a poly(A) tail of about 140 nucleotides.
  • the antisense oligonucleotides of the invention may be synthesized by any of the known chemical oligonucleotide synthesis methods. Such methods are generally described, for example, in Winnacker, From Genes to Clones: Introduction to Gene Technolog . VCH Verlagsgesellschaft mbH (H. Ibelgaufts trans. 1987) .
  • any of the known methods of oligonucleotide synthesis may be utilized in preparing the instant antisense oligonucleotides.
  • the antisense oligonucleotides are most advantageously prepared by utilizing any of the commercially available, automated nucleic acid synthesizers.
  • One such device, the Applied Biosystems 380B DNA Synthesizer utilizes 3-cyanoethyl phosphoramidite chemistry. Since the complete nucleotide synthesis of DNA complementary to the c-mvb mRNA transcript is known, antisense oligonucleotides hybridizable with any portion of the mRNA transcript may be prepared by oligonucleotide synthesis methods known to those skilled in the art.
  • oligonucleotide While any length oligonucleotide may be utilized in the practice of the invention, sequences shorter than 12 bases may be less specific in hybridizing to the target c-myb mRNA, may be more easily destroyed by enzymatic digestion, and may be destabilized by enzymatic digestion. Hence, oligonucleotides having 12 or more nucleotides are preferred. Long sequences, particularly sequences longer than about 40 nucleotides, may be somewhat less effective in inhibiting c-myb translation because of decreased uptake by the target cell. Thus, oligomers of 12-40 nucleotides are preferred, more preferably 15-30 nucleotides, most preferably 18-26 nucleotides. Sequences of 18-21 nucleotides are most particularly preferred.
  • Oligonucleotides complementary to and hybridizable with any portion of the c-myb mRNA transcript are, in principle, effective for inhibiting translation of the transcript, and capable of inducing the effects herein described. It is believed that translation is most effectively inhibited by blocking the mRNA at a site at or near the initiation codon. Thus, oligonucleotides complementary to the 5'- terminal region of the c-myb mRNA transcript are preferred. It is believed that secondary or tertiary structure which might interfere with hybridization is minimal in this region.
  • sequences that are too distant in the 3'-direction from the initiation site may be less effective in hybridizing the mRNA transcripts because of a "read-through” phenomenon whereby the ribosome is postulated to unravel the antisense/sense duplex to permit translation of the message. See, e.g., Shakin, J. Biochemistry 261. 16018 (1986).
  • the antisense oligonucleotide is preferably directed to a site at or near the initiation codon for protein synthesis. Oligonucleotides complementary to the c-myb mRNA, including the . initiation codon (the first codon at the 5' end of the translated port: ai of the c-myb transcript, comprising nucleotides 114-116 of the complete transcript) are preferred.
  • antisense oligomers complementary to the 5'-terminal region of the c-myb transcript are preferred, particularly the region including the initiation codon, it should be appreciated that useful antisense oligomers are not limited to those complementary to the sequences found in the translated portion (nucleotides 114 to 2031) of the mRNA transcript, but also includes oligomers complementary to nucleotide sequences contained in, or extending into, the 5'-and 3'-untranslated regions. Oligomers whose complementarity extends into the 5'-untranslated region of the c-myb transcript are believed particularly effective in inhibiting c-mvb translation.
  • Preferred oligonucleotides complementary to the 5'-untranslated region of the transcript include molecules having a nucleotide sequence complementary to a portion of the c-myb mRNA transcript including the cap nucleotide, that is, the nucleotide at the extreme 5'-end of the transcript.
  • the SI nuclease assay procedure of Molecular Cloning. 2nd edition (Sambrook et a_L. , Eds. 1989), pages 7.66-7.70 (incor- porated herein by reference) was essentially followed to map the location of c-myb cap sites using mRNA isolated from the leukemic cell line CCRF-CEM, which expresses high levels of c-mvb mRNA.
  • nucleotide sequence of the mRNA transcript 5'-terminus beginning with the cap nucleotide may be readily established, and antisense oligonucleotides complementary and hybridizable thereto may be prepared.
  • the following 40-mer oligodeoxynucleotide is complementary to the c-myb mRNA transcript beginning with the initiation codon of the transcript and extending downstream thereof (in the 5' direction): SEQ ID NO:l.
  • oligomers based upon the above sequence, in particular, oligomers hybridizable to segments of the c-myb message containing the initial codon, may be utilized. Particularly preferred are the following 26- to 15-mers:
  • Oligodeoxynucleotides complementary to the c-myb mRNA transcript beginning with the second codon of the translated portion of the transcript (nucleotides 117-119 of the complete transcript) are another group of preferred oligomers.
  • Such oligomers include, for example, the following 21- to 15-mers:
  • oligonucleotide employed may represent an unmodified oligonucleotide or an oligonucleotide analog.
  • oligonucleotides hybridizable to the c- myb mRNA transcript finding utility according to the present invention include not only oligomers of the biologically significant native nucleotides, i.e., A, dA, G, dG, C, dC, T and ⁇ , but also oligonucleotide species which have been modified for improved stability and/or lipid solubility.
  • lipid solubility and/or resistance to nuclease digestion results by substituting an alkyl or alkoxy group for a phosphate oxygen in the internucleotide phosphodiester linkage to form an alkylphosphonate o 1 i gonuc 1 e o s i de or alkylphosphotriester oligonucleotide.
  • the phosphoro- thioates in particular, are stable to nuclease cleavage and soluble in lipid. They may be synthesized by known automatic synthesis methods.
  • Non-ionic oligonucleotides such as these are characterized by increased resistance to nuclease hydrolysis and/or increased cellular uptake, while retaining the ability to form . stable complexes with complementary nucleic acid sequences.
  • the alkyl- phosphonates in particular, are stable to nuclease cleavage and soluble in lipid.
  • the preparation of alkylphosphonate oligonucleosides is disclosed in U.S. Patent 4,469,863.
  • the methylphosphonates in particular, are preferred.
  • Methylphosphonate oligomers can be prepared by a variety of methods, both in solution and on insoluble polymer supports (Agrawal and Riftina, Nucl. Acids Res.. 6, 3009-3024 (1979); Miller et a__. , Biochemistry. 18, 5134-5142 (1979), Miller et al. , J. Biol. Chem.. 255, 9659-9665 (1980); Miller et a_L. , Nucl. Acids Res.. 11, 5189-5204 (1983), Miller et al.. Nucl. Acids Res.. 11, 6225-6242 (1983), Miller et al.
  • methylphosphonate oligonucleosides The most efficient procedure for preparation of methylphosphonate oligonucleosides involves use of 5 ' -0_-dimethoxytrityldeoxynucleoside-3 ' -0_- diisopropylmethylphosphoramidite intermediates, which are similar to the methoxy or S-cyanoethyl phosphoramidite reagents used to prepare oligodeoxy- ribonucleotides.
  • the methylphosphonate oligomers can be prepared on controlled pore glass polymer supports using an automated DNA synthesizer (Sarin et al., Proc. Natl. Acad. Sci. USA. 85, 7448-7451 (1988)).
  • Resistance to nuclease digestion may also be achieved by modifying the internucleotide linkage at both the 5' and 3' termini with phosphoroamidites according to the procedure of Dagle et al., Nucl. Acids Res. 18. 4751-4757 (1990).
  • Suitable nucleotide analogs for preparation of the antisense oligonucleotides described herein include but are not limited to the ethyl or methyl phosphonate analogs disclosed in U.S. Patent No. 4,469,863.
  • Phosphorothioate oligonucleotides contain a sulfur-for-oxygen substitution in the internucleotide phosphodiester bond. Phosphorothioate oligonucleotides combine the properties of effective hybridization for duplex formation with substantial nuclease resistance, while retaining the water solubility of a charged phosphate analogue. The charge is believed to confer the property of cellular uptake via a receptor (Loke et al. , Proc. Natl. Acad. Sci. U.S.A. 86. 3474-3478 (1989)).
  • Phosphorothioate modified oligodeoxynu ⁇ cleotide are described by LaPlanche, et al. , Nucleic Acids Research 14, 9081 (1986) and by Stec et al. , J. Am. Chem. Soc. 106, 6077 (1984) .
  • the general synthetic method for phosphorothioate oligonucleotides was modified by Stein et al. , Nucl. Acids Res.. 16, 3209-3221 (1988), so that these compounds may readily be synthesized on an automatic synthesizer using the phosphoramidite approach.
  • oligoribonucleotide analogues mean that other agents may also be used for the purposes described here, e.g., 2'-0-methylribonucleotides (Inove et al. , Nucleic Acids Res. 15, 6131 (1987) and chimeric oligonucleotides that .are composite RNA-DNA analogues (Inove et al. , FEBS Lett. 215, 327 (1987).
  • oligodeoxyribonucleotides are preferred in the practice of the present invention. Oligo ⁇ deoxyribonucleotides are further preferred because, upon hybridization with c-myb mRNA, the resulting DNA- RNA hybrid duplex is a substrate for RNase H, which specifically attacks the RNA portion of DNA-RNA hybrid. Degradation of the mRNA strand of the duplex releases the antisense oligodeoxynucleotide strand for hybridization with additional c-mvb messages.
  • the antisense oligonucleotides of the present invention will have a sequence which is completely complementary to the target portion of the c-myb message. Absolute complementarity is not however required, particularly in larger oligomers.
  • reference herein to a "nucleotide sequence complementary to at least a portion of the mRNA transcript" of c-myb does not necessarily mean a sequence having 100% complementarity with the transcript.
  • any oligonucleotide having sufficient complementarity to form a stable duplex with c-mvb mRNA is suitable. Stable duplex formation depends on the sequence and length of the hybridizing oligonucleotide and the degree of complementarity with the target region of the c-myb message.
  • One skilled in the art may readily determine the- degree of mismatching which may be tolerated between any given antisense oligomer and the target c-mvb message sequence, based upon the melting point, and therefore the stability, of the resulting duplex. Melting points of duplexes of a given base pair composition can be readily deter- mined from standard texts, such as Molecular Cloning: A Laboratory Manual. (2nd edition, 1989) , J. Sambrook et al. , eds.
  • oligonucleotides capable of stable hybridization with any region of the c-myb message are within the scope of the present invention, oligonucleotides complementary to a region including the initiation codon are believed particularly effective. Particularly preferred are oligonu ⁇ cleotides hybridizable to a region of the c-myb mRNA up to 40 nucleotides upstream (in the 5' direction) of the initiation codon or up to 40 nucleotides downstream (in the 3' direction) of that codon.
  • the antisense oligonucleotides of the invention have been observed to inhibit normal human hematopoiesis. However, they inhibit the growth of c- myb colorectal carcinoma cells at a significantly lower concentration than such normal cells. As hereinafter established, normal colon cells do not express detectable levels of c-myb transcript. Their growth would not therefore be inhibited by c-myb antisense at selected dosages fatal to colon carcinoma cells. This pharmaceutically significant differential sensitivity makes the instant oligonucleotides useful in treating colorectal carcinoma.
  • the antisense oligonucleotides may be combined with a pharmaceutical carrier, such as a suitable liquid vehicle or excipient and an optional auxiliary additive or additives.
  • a suitable liquid vehicle or excipient such as distilled water, physiological s : ...ine, aqueous solution of dextrose, and the like.
  • the c-myb mRNA antisense oligonucleotides are preferably administered parenterally, most preferably intra ⁇ venously.
  • the vehicle is designed accordingly.
  • direct intra-arterial administration of oligonucleotides may be utilized.
  • Other possible routes of oligomer administration include rectal and oral.
  • the antisense oligonucleotides may be administered by a variety of specialized oligonucleotide delivery techniques.
  • oligonucleotides may be encapsulated in liposomes for therapeutic delivery.
  • the oligonucleotide depending upon its solubility, may be present both in the aqueous layer and in the lipidic layer, or in what is generally termed a liposomic suspension.
  • the hydrophobic layer generally but not exclusively, comprises phospholipids such as lecithin and sphin- gomyelin, steroids such as cholesterol, ionic surfactants such as diacetylphosphate, stearylamine, or phosphatidic acid, and/or other materials of a hydrophobic nature.
  • Oligonucleotides have been successfully encapsulated in unilameller liposomes.
  • Reconstituted Sendai virus envelopes have been successfully used to deliver RNA and DNA to cells. Arad et al. , Biochem. Biophy. Acta. 859, 88-94 (1986) .
  • Antisense oligomers have also been delivered in the form of poly(L-lysine) conjugates. Such conjugates are described by Lemaitre et al. , Proc. Natl. Acad. Sci. USA. 84, 648-652 (1987).
  • the c-mvb antisense oligonucleotides may be administered in a dosage effective for inhibiting the proliferation of colorectal carcinoma cells in the afflicted individual, while maintaining the viability of normal cells. Such amounts may vary depending on the nature and extent of the neoplasm, the particular oligonucleotide utilized, and other factors.
  • the actual dosage administered may take into account the size and weight of the patient, whether the nature of the treatment is prophylactic or therapeutic in nature, the age, health and sex of the patient, the route of administration, and other factors. Those skilled in the art should be readily able to derive appropriate dosages and schedules of administration to suit the specific circumstance and needs of the patient.
  • LoVo, Colo 205 and HT 29 cell lines all of which are derived from human colon adenocarcinomas (Trainer et al. , Int. J. Cancer 41, 287-296 (1988)) were utilized in the following experiments.
  • Doxorubicin resistance was induced in a portion of LoVo cells to form the LoVo/Dx subline by prolonged culture in medium containing doxorubicin according to the procedure of Grandi et al. , Br. J. Cancer 54, 515- 518 (1986).
  • Cells were cultured in Ham's F 12 medium (Gibco) supplemented with 10% fetal calf serum (Biological Industries) , pretreated for 15 min. at 65°C with 2mM glutamine and antibiotics (MA Bioprod- ucts) .
  • 3 x 10 4 cells were seeded in 24 well plates (Costar) and c-mvb sense(S) (SEQ ID NO:21) or antisense (AS) oligodeoxynucleotides (SEQ ID NO:17) were added to the culture medium for 3 days at 40 ⁇ g/ml, 30 ⁇ g/ml and 20 ⁇ g/ml, respectively.
  • the S and AS oligonucleotides correspond to codons 2-7 of the translated c-myb message.
  • Cells were exposed to three different decreasing doses of AS to obtain concentrations which were 1/3, 1/10 and 1/40 of the initial dosage described above (40 ⁇ g/ml) .
  • Sense oligomers were only given at the highest dose.
  • Control cells were cultured in the same conditions without oligodeoxynucleotides. After 3 days, cells were recovered by mechanical detachment, counted and analyzed for viability by trypan blue dye exclusion.
  • 3 x 10 4 S- and AS-treated and untreated cells were washed after treatment with oligodeoxynucleotides, pulsed with 8 H- TdR (1 ⁇ Ci/well) and incubated for 6 hours at 37 * C. Cells were then washed and fixed on glass fiber dishes by using a cell-harvester apparatus (Titertek Cell Harvester 550, Flow Laboratories) . Radioactivity was measured using a beta counter. Non-specific radioactivity was measured in the culture medium and eliminated from the counts.
  • Example 2 Measurement of c-mvb Expression Steady-state c-myb mRNA levels were measured by Northern blot analysis of LoVo, LoVo/Dx, Colo 205 and HT 29 human carcinoma cell lines as follows. Simultaneous isolation of RNA and DNA from the above- identified colon carcinoma cell lines, and from fresh normal colonic mucosa, was performed by the guanidine isothiocyanate/cesium chloride method. (Davis et al. , Basic Method in Molecular Biology (Elsevier, New York, 1986) .
  • RNA (20 ⁇ g) was denatured, separated on 1% agarose/formaldehyde gel and transferred to nylon filters (Hybond N, A ersham) . Nucleic acids were bound to filters at 80°C for 2 hrs. Prehybridization and Northern blot hybridization were performed as described by Colombo et al. , Immunogenetics. 26, 99- 104 (1987). Filters were washed twice in 2X SSC/0.1% SDS at room temperature for 15 min. and then two or three times in 0.2X SSC/1.0% SDS at 52°C for 30 min. To quantitate c-myb expression, densitometric scanning of the Northern blots was performed on a LKB Ultroscan XL.
  • LoVo/Dx cells was demonstrated by RT-PCR and Southern blotting of the PCR products.
  • RNA was extracted from 3-8 x 10 5 LoVo/Dx cells treated with c-myb oligodeoxynucleotide as above. RNA was precipitated with 20 ⁇ g of E.
  • BRL Moloney murine leukemia virus reverse transcriptase
  • PCR Sixty cycles of PCR were performed in a Perkin Elmer Thermal Cycler by annealing at 55°C, synthesizing at 72 ⁇ C and denaturing at 95°C. Positive and negative controls were used to exclude amplification of contaminating sequences.
  • the PCR products were separated on a 2% Nusieve agarose gel and transferred to a nylon filter (Hybond N, Amersham) by alkaline blotting. The resulting blot was hybridized at 50°C with a 50-mer c-myb synthetic oligonucleotide probe (made by a DNA synthesizer) complementary to c-myb cDNA from nucleotides 2,351 to 2,400.
  • the probe was 5'end-labelled with T4 polynucleotide kinase (Promega Biotech, Madison, WI) and ⁇ - 32 P-ATP. After hybridization, the filters were washed in 2X SSC/0.1% SDS at room temperature for 10 min. and once at 50"C for 30 min. before overnight exposure to X-ray films at 80 ⁇ C.
  • LoVo/DX cells Analysis of c-myb mRNA levels in the oligodeoxynucleotide-treated and untreated LoVo/DX cells revealed the presence of c-myb transcripts in untreated or c-myb sense-treated cells but not in LoVo/Dx cells exposed to c-myb antisense oligodeoxynucleotide. 2-Microglobulin mRNA levels were constant in all the samples. This demonstrates the specific inhibition of gene expression by anti ⁇ sense oligodeoxynucleotides.
  • c- myb gene function is required for proliferation of colon carcinoma cells expressing c-myb.
  • the role of c-myb is thus not limited to cells of hematopoietic origin.
  • the proliferation of colon carcinoma cells expressing c-myb can be effectively suppressed with antisense oligonucleotides.
  • the dose of antisense exerting an inhibitory effect is related to the level of c-myb mRNA expression, proliferation of colon carcinoma cells, and therefore the attendant ti ⁇ mor growth and disease progression, is maintained by high levels of c-myb expression.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

On traite un carcinome colo-rectal en administrant des oligonucléotides présentant une séquence nucléotidique complémentaire à au moins une partie de la transcription de l'ARNm du gène humain c-myb. Ces oligonucléotides peuvent être hybridés avec la transcription d'ARNm de c-myb.
EP92913962A 1991-05-23 1992-05-22 Treatment of colorectal carcinoma with antisense oligonucleotides to c-myb proto-oncogene Withdrawn EP0585399A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70486291A 1991-05-23 1991-05-23
US704862 1991-05-23

Publications (2)

Publication Number Publication Date
EP0585399A1 true EP0585399A1 (fr) 1994-03-09
EP0585399A4 EP0585399A4 (en) 1995-11-15

Family

ID=24831149

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92913962A Withdrawn EP0585399A4 (en) 1991-05-23 1992-05-22 Treatment of colorectal carcinoma with antisense oligonucleotides to c-myb proto-oncogene

Country Status (4)

Country Link
EP (1) EP0585399A4 (fr)
JP (1) JPH06508130A (fr)
CA (1) CA2109829A1 (fr)
WO (1) WO1992020348A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5658780A (en) 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
AU685074B2 (en) * 1992-12-14 1998-01-15 Start Technology Partnership Administration of oligonucleotides antisense to dopamine receptor MRNA for diagnosis and treatment of neurological pathologies
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
US5994320A (en) * 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
GB9504598D0 (en) 1995-03-03 1995-04-26 Imp Cancer Res Tech Method of nucleic acid analysis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005445A1 (fr) * 1988-11-07 1990-05-31 Temple University Of The Commonwealth System Of Higher Education Oligonucleotides non codants du proto-oncogene c-myb et leurs emplois

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740463A (en) * 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005445A1 (fr) * 1988-11-07 1990-05-31 Temple University Of The Commonwealth System Of Higher Education Oligonucleotides non codants du proto-oncogene c-myb et leurs emplois

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RES 51 (11), 2897-2901., 1 June 1991 MELANI, C. ET AL. 'INHIBITION OF PROLIFERATION BY C- MYB ANTISENSE OLIGODEOXYNUCLEOTIDES IN COLON ADENOCARCINOMA CELL LINES THAT EXPRESS C-MYB.' *
PROC AM ASSOC CANCER RES ANNU MEET 32 (0), 428;, March 1991 MELANI, C. ET AL. 'C-MYB EXPRESSION IN HUMAN COLON CARCINOMA CELL LINES AND EFFECT OF C- MYB ANTISENSE OLIGONUCLEOTIDE ON CELL PROLIFERATION.' *
See also references of WO9220348A1 *

Also Published As

Publication number Publication date
CA2109829A1 (fr) 1992-11-26
JPH06508130A (ja) 1994-09-14
WO1992020348A1 (fr) 1992-11-26
EP0585399A4 (en) 1995-11-15

Similar Documents

Publication Publication Date Title
US5831066A (en) Regulation of bcl-2 gene expression
US5734039A (en) Antisense oligonucleotides targeting cooperating oncogenes
US5618709A (en) Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
US5652222A (en) Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
EP0722342B1 (fr) REGULATION DE L'EXPRESSION DU GENE bcl-2
EP0841068A1 (fr) Inhibiteur de la croissance de cellules leucemiques contenant des derives oligonucleotidiques antisens agissant contre le gene de la tumeur de wilms (wt1)
EP1240322A2 (fr) Utilisations therapeutiques d'oligonucleotides a lna modifie
WO1998014615A1 (fr) Modulation oligonucleotidique antisens de l'expression genique a glyproteine-p resistant a plusieurs drogues (mdr)
EP0668782B1 (fr) Combinaison d'un agent anti-neoplasique et d'oligonucleotides antisens dans le traitement du cancer
EP0585399A1 (fr) Traitement de carcinome colo-rectal a l'aide d'oligonucleotides non codants par rapport au proto-oncogene c-myb
KR100199247B1 (ko) Ras 유전자의 안티센스 올리고뉴클레오티드 저해
US5612212A (en) Selective inhibition of cell proliferation by vav antisense oligonucleotides
AU3070992A (en) Treatment of melanoma with antisense oligonucleotides to c-myb proto-oncogene
JPH09104629A (ja) ウイルムス腫瘍遺伝子（ｗｔ１）に対するアンチセンスオリゴヌクレオチド誘導体を含んで成る白血病細胞増殖阻害剤
WO1995024223A1 (fr) Inhibition de la proliferation cellulaire par des oligonucleotides non codants specifiques contre e2f-1
WO1998013072A1 (fr) Compositions et procedes destines au traitement de la resistance multiple aux anticancereux
WO1994004137A1 (fr) Oligonucleotides non codant complementaires du proto-oncogene de cycline d1
KR102680316B1 (ko) 안티센스 올리고뉴클레오타이드
US7314927B2 (en) Regulation of bcl-2 gene expression
US20020165196A1 (en) Oligonucleotide inhibitors of cancer cell proliferation
WO1994007538A1 (fr) OLIGONUCLEOTIDES NON CODANTS DU PROTO-ONCOGENE B-m^_y^_b^

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931028

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19950929

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19960802